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Introduction: A retrospective analysis of the outcomes of stereotac-
tic body radiation therapy (SBRT) in the treatment of large (>3 cm) 
non–small-cell lung cancers (NSCLCs).
Methods: Between February 2007 and November 2011, 63 patients 
with T2-T4N0 NSCLC were treated with SBRT. Toxicity was graded 
per Common Terminology Criteria for Adverse Events, version 4.0. 
Local failure-free survival (LFFS), recurrence-free survival, and 
overall survival curves were estimated using the Kaplan–Meier 
method and univariate analysis was performed using Cox regression.
Results: Median follow-up was 16.9 months. One- and 2-year LFFS 
was 88.8% and 75.7%, 1- and 2-year recurrence-free survival was 
59.0% and 41.6%, and 1- and 2-year overall survival was 77.1% and 
57.6%, respectively. Planning target volume less than 106 cm3 was 
associated with a significantly higher 1- and 2-year LFFS (p =0.05). 
Grade 2 or higher acute and late pulmonary toxicities occurred in 
19.3% and 19.3% of patients, respectively, and were not associated 
with common dose–volume parameters; 22.8% of patients developed 
grade 2 or higher chest wall pain, which was significantly associated 
with chest wall V30 70 cm3 or more (p = 0.03).
Conclusions: SBRT for larger NSCLC tumors achieves high LFFS 
with acceptable toxicity. LFFS was worse with planning target vol-
ume 106 cm3 or more. Grade 2 or higher chest wall pain was associ-
ated with chest wall V30 70 cm3 or more.
Key Words: Stereotactic body radiation therapy, Lung cancer, Large 
tumors.
(J Thorac Oncol. 2013;8: 1396–1401)
The use of definitive conventional radiotherapy for inoper-able early-stage lung cancer has achieved historically poor 
results and inferior local control compared with surgery, espe-
cially among larger tumors.1–4 The advent of hypofractionated 
stereotactic body radiation therapy (SBRT) has dramatically 
improved both local control and overall survival (OS) among 
inoperable early-stage lung cancer patients.5–7 Currently, the 
results of SBRT rival those of surgical resection, and ran-
domized trials comparing these two definitive approaches are 
ongoing.8 Most studies on SBRT have focused on tumors less 
than 5 cm in maximum diameter. However, the outcome and 
toxicity of treatment for tumors larger than 3 cm are underrep-
resented in the current literature. The purpose of the current 
study is to retrospectively analyze our institutional experience 
for patients with large (>3 cm) non–small-cell lung cancers 
(NSCLCs) treated with definitive SBRT.
MATERIALS AND METHODS
Inclusion Criteria
We identified 63 patients with primary node-neg-
ative NSCLC with tumors greater than 3 cm as measured 
by staging computed tomography (CT) scan in a single 
axial, coronal, or sagittal dimension, which were treated 
with image-guided SBRT between February 2007 and 
November 2011 at Memorial Sloan-Kettering Cancer 
Center (MSKCC). All patients underwent a detailed stag-
ing workup including a full history and physical examina-
tion by the radiation oncologist, pathology review, CT scan 
of the chest, positron emission tomography (PET)/CT scan 
and magnetic resonance imaging of the brain. Suspicious-
appearing lymph nodes on PET/CT scan were assessed with 
invasive mediastinal staging when indicated. Exclusion cri-
teria included history of prior radiation therapy to the same 
lesion, or treatment with less than three or more than five 
fractions. Three patients with M1 disease, whose metastatic 
disease was controlled and whose primary lung tumor was 
treated with SBRT, were included. Patient and tumor char-
acteristics are detailed in Table 1.
Treatment
All patients were immobilized using a patient-specific 
alpha cradle or stereotactic body frame, which has been 
described elsewhere.9 Patients underwent a respiratory-cor-
related CT simulation and treatment was planned with the 
MSKCC in-house treatment-planning system.10,11 The gross 
tumor volume (GTV) was contoured and modified based on 
the respiratory-correlated CT scan to generate an internal 
target volume. The clinical target volume included the inter-
nal target volume plus a 2- to 3-mm margin for microscopic 
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disease extension, and the planning target volume (PTV) 
included the clinical target volume plus 5-mm margin to 
account for setup error. Normal tissue constraints included 30 
Gy maximal point dose to the esophagus, trachea, and main-
stem bronchus. For patients undergoing 45 Gy in five frac-
tions, a maximal point dose of 45 and 9 Gy per fraction to 
these structures was permissible at the physician’s discretion. 
The spinal cord was constrained to a maximal point dose of 
24 Gy. Lung constraints included ipsilateral V20 25% or less 
and total lung V20 12% or less. Hot spots were not permitted 
outside the PTV.
Typically, treatment was delivered with sliding window 
intensity-modulated radiation therapy using four to six copla-
nar 6 MV beams on Varian linear accelerators (LINACs). Dose 
was prescribed to the 100% isodose line surrounding the PTV. 
Inhomogeneity corrections were applied using a path-length–
corrected pencil beam calculation.10 The median dose pre-
scribed was 48 Gy, ranging from 40 to 60 Gy in three to five 
fractions. Typical dose regimens of our risk-adapted approach 
were 9 Gy × 5 fractions (n = 18) for tumors within 2 cm from the 
proximal bronchial tree, 12 Gy × 4 fractions (n = 24) for tumors 
within 1 cm from the chest wall, and 18 to 20 Gy × 3 fractions (n 
= 15) for all other peripherally located tumors, delivered every 
other day. All LINACs used for treatment had a kilovoltage 
imaging capability (Varian On-Board Imager, Varian Medical 
Systems, Palo Alto, CA). After initial setup, a cone-beam CT 
scan was acquired, and the GTV as seen on the cone-beam CT 
was registered to the planning scan GTV. Shifts were performed 
to correct for setup errors more than 2 mm in any direction. An 
example of treatment plan is shown in Figure 1.
Follow-Up
Patients were followed with a detailed history and phys-
ical examination, typically every 3 months for the first 2 years, 
and every 6 to 12 months thereafter. Toxicities were graded 
per the National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 4.0, and included respi-
ratory toxicities (cough, dyspnea, radiation pneumonitis) and 
chest wall pain. Acute events were defined as occurring within 
4 months of the end of radiation therapy, and late events were 
defined as events occurring greater than 4 months after the 
end of radiation therapy.
A chest CT scan was performed at each follow-up visit, 
and patients who had suspicious findings on the CT scan 
were referred for a PET-CT when possible. Local failure was 
defined at the time of radiographic progression of the primary 
tumor, based on the interpretation of the radiologist. Regional 
failure was defined as the development of nodal disease within 
the hilum, mediastinum or supraclavicular fossa. Recurrence 
was defined as either radiographic local, nodal, or distant fail-
ure. Patients were censored at the date of last follow-up with 
no progression.
TABLE 1.  Patient and Tumor Characteristics
No. %
Age Median 80
Range 58–95
Sex Male 29 46
Female 34 54
KPS Median 80
Range 50–100
Stage IB 51 81
IIA 3 5
IIB 4 6
IIIA 2 3
IV (all with T2a 
tumors)
3 5
Size (cm) Median 3.9
Range 3.1–8.5
Histology Adenocarcinoma 43 68
SCC 20 32
KPS, Karnofsky performance status; SCC, squamous cell carcinoma.
FIGURE 1.  An 85-year-old man with stage IIA non–small-cell lung cancer. The primary tumor was 5.5 cm in the greatest 
dimension as measured on a simulation computed tomography scan. The patient was treated with stereotactic body radiation 
therapy with 12 Gy × 4 fractions. The beam arrangement and isodose lines in the axial, sagittal, and coronal planes are shown 
above. ANT, anterior; SUP, superior.
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Analysis
Local failure-free survival (LFFS) was defined as the 
time from the end date of SBRT until the date of local pro-
gression or the date of last scan with no local progression. 
Recurrence-free survival (RFS) was defined as the time from 
the end date of SBRT until the date of any recurrence (includ-
ing local, regional, or distant metastases), or the date of last 
follow-up. OS was defined as the time from end of SBRT until 
the date of death or last follow-up. Time to respiratory toxic-
ity and time to chest wall pain were both analyzed as times 
to event, starting at the end date of SBRT until the date of 
development of the toxicity or the date of last follow-up, in 
the absence of toxicity.
The association of tumor and radiographic characteris-
tics with clinical outcomes and the development of toxicity 
were estimated by Kaplan–Meier methods and analyzed by 
Cox regression. A log-rank test was performed if there were 
no events in one comparison group.
Clinical cut points for PTV have not been well described. 
An optimal threshold value for PTV with respect to LFFS 
was obtained by the method of the maximally selected log-
rank statistic. Briefly, multiple cutoff values were selected, 
and log-rank tests were repeated to maximize the statistic. 
To account for the multiple testing involved in the cut point 
search, the log-rank p value for the comparison of groups 
above and below this cut point was adjusted by the method 
described in the study by Lausen and Schumacher.12 The cut 
point that maximized the log-rank test was PTV of 106 cm3, 
which corresponds to a sphere with a maximum single cross-
sectional dimension of 5.9 cm. The association of PTV with 
all other outcomes was analyzed as a dichotomous variable at 
this cut point.
Maximal axial tumor diameter was categorized at 
clinically relevant cut points (3–4, 4–5, and ≥5 cm) for 
association with the outcomes by Cox regression analysis. 
Volume of chest wall receiving 30 Gy (V30) was dichoto-
mized at a predetermined clinically relevant cut point of 
less than 70 and 70 cm3 or more based on a previous study 
from our institution, demonstrating an increased risk of the 
development of chest wall pain when the chest wall V30 was 
greater than 70 cm3.13
RESULTS
Clinical Outcomes
The median follow-up was 17.1 months (range, 1.3–
39.8) for patients alive and 16.9 months (range, 1.3–44.8) 
for the entire cohort. One- and 2-year LFFS was 88.8% and 
75.7%, respectively. One- and 2-year RFS was 59.0% and 
41.6%, respectively. One- and 2-year OS was 77.1% and 
57.6%, respectively. Three patients experienced simultane-
ous regional and local failure, and one patient experienced 
simultaneous distant and local failure. All other patients who 
experienced regional or distant failure (n = 20) were locally 
controlled.
LFFS was significantly worse in tumors with the PTV 
more than 106 cm3, compared with that in tumors with PTV of 
106 cm3 or less (2-year LFFS rate 56% versus 100%, adjusted 
p = 0.05; Fig. 2). There was no association between LFFS 
and biologically effective dose, assuming an α/β ratio of 10 
(BED
10
), GTV size, or maximal axial tumor diameter. There 
were also no statistically significant associations between 
BED
10
, GTV volume, PTV volume, and maximal axial diam-
eter of tumor with respect to RFS or OS. These results are 
summarized in Table 2.
Toxicity
Treatment was generally well tolerated given the high 
radiotherapy dose delivered and the substantial size of the 
tumor targets. Fifty-seven patients were analyzed for toxicity, 
and six patients were excluded because of a history of lung 
radiation. Eleven of 57 patients (19.3%) experienced grade 
2 or higher acute pulmonary toxicity, with an equal number 
of patients experiencing grade 2 or higher late toxicity. Four 
patients had acute pulmonary toxicity extending beyond 4 
months after SBRT and were counted toward both the acute 
and late toxicity endpoint, whereas nine patients experienced 
acute toxicity without late toxicity, and nine other patients 
experienced late toxicity without acute toxicity. One patient 
developed grade 4 radiation pneumonitis requiring hospital-
ization and intubation, in the setting of superimposed bac-
terial and influenzal pneumonia, with full clinical recovery. 
There were no grade 5 toxicities. Toxicity data are reported 
in Table 3.
There were no statistically significant associations 
between the development of respiratory toxicities and com-
mon dose–volume parameters, including ipsilateral V20 Gy, 
overall V20 Gy, total lung V1050 cGy, or PTV size.
Grade 2 or higher chest wall pain was experienced in 
22.8% of patients. There was a strong association between 
chest wall V30 70 cm3 or more and the development of chest 
FIGURE 2.  Local failure-free survival by PTV. PTV, planning 
target volume.
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wall pain (p = 0.03), Figure 3. There were no significant asso-
ciations between the development of chest wall pain and PTV 
volume or maximal axial tumor diameter.
DISCUSSION
Although SBRT has gained widespread acceptance in 
the nonsurgical treatment of early-stage lung cancer, its role 
in the treatment of larger tumors is not well described. In this 
retrospective study, we analyzed our institutional experience 
of treating tumors greater than 3 cm. To our knowledge, this is 
the largest study to report exclusively on large tumors treated 
with SBRT. In this study, LFFS was significantly worse, with 
a statistically identified PTV cutoff of 106 cm3, and the devel-
opment of chest wall pain was correlated with chest wall V30 
greater than 70 cm3.
Radiation therapy with conventional fractionation has 
generally achieved inferior local control and OS when com-
pared with outcomes after surgery. Kaskowitz et al.3 analyzed 
53 patients with stage I NSCLC treated with radiation therapy 
alone to a median dose of 63.2 Gy (range, 39.9–79.2) and 
reported a 3-year freedom from local progression of 51% and 
5-year OS of 6%. Investigators from Duke University reported 
on 141 patients treated with external beam radiation therapy. 
With a median follow-up of 2 years, 42% of patients failed 
locally, and the estimated 5-year OS was 13%.2 Both of these 
studies suggested improved outcomes with doses greater than 
65 Gy, providing the rationale for dose-escalation studies 
from the Radiation Oncology Therapy Group (RTOG)14 and 
MSKCC.15,16 Bradley et al.14 used three-dimensional con-
formal radiation therapy (3DCRT) to treat 179 patients with 
inoperable NSCLC that were stratified into groups based on 
the V20 of the treatment plan, and successfully escalated dose 
from 70.9 to 83.8 Gy with acceptable toxicity in patients with 
V20 less than 25% and from 70.9 to 77.4 Gy in patients with 
V20 25% to 36%. Rosenzweig et al.15 conducted a similar 
phase I trial in 104 patients and successfully dose escalated 
from 70.2 to 84.0 Gy, achieving an excellent local control rate 
of 88% at 2 years for patients with stage I/II disease and dem-
onstrating an OS benefit for patients treated with doses 80 Gy 
or more (p = 0.05). Sura et al.16 analyzed 82 patients (41 of 
whom were enrolled in the original MSKCC dose-escalation 
trial) who were treated with 3DCRT with doses of 80 Gy or 
more and confirmed favorable local control (67% at 5 years) 
and OS (36% at 5 years) along with an acceptably low grade 3 
or higher acute (5%) and late (7%) pulmonary toxicity.
TABLE 3.  Toxicity (n = 57)
Grade 2
N (%)
Grade 3
N (%)
Grade 4
N (%)
Grade 5
N (%)
Grade ≥2
N (%)
Acute pulmonary 
toxicity
7 (12.3) 3 (5.3) 1 (1.8) 0 (0) 11 (19.3)
Late pulmonary 
toxicity
7 (12.3) 4 (7.0) 0 (0) 0 (0) 11 (19.3)
Chest wall pain 7 (12.3) 6 (10.5) 0 (0) 0 (0) 13 (22.8)
FIGURE 3.  Time to chest wall pain by volume of chest wall 
receiving 30 Gy (V30).
TABLE 2.  Univariate Cox Regression Analyses for LFFS, RFS, and OS
N
LFFS RFS OS
HR (95% CI) p HR (95% CI) p HR (95% CI) p
BED
10
<100 23 1.00 0.73 1.00 0.33 1.00 0.87
≥100 40 0.80 (0.21–2.97) 1.49 (0.68–3.27) 1.07 (0.48–2.39)
GTV size (cm3) Continuous 63 1.01 (0.98–1.03) 0.58 1.01 (1.00–1.02) 0.14 1.01 (1.00–1.02) 0.14
PTV size (cm3) ≤106 27 N/A 0.05 1.00 0.09 1.00 0.95
>106 36 N/Aa 1.94 (0.9–4.19) 1.02 (0.48–2.17)
Max tumor diameter 
(3 groups)
3–4 cm 35 1.00 0.89 1.00 0.74 1.00 0.14
4–5 cm 21 1.01 (0.24–4.25) 1.12 (0.49–2.53) 1.72 (0.78–3.80)
≥5 cm 7 1.68 (0.19–14.58) 1.55 (0.52–4.67) 2.96 (0.92–9.47)
There are nine local failures, 29 regional failures, and 30 deaths for LFFS, RFS, and OS, respectively.
aHRs are not available because there are no events in one group. Refer to Kaplan–Meier curves and adjusted log-rank p value.
BED10, biologically effective dose assuming an α/β ratio of 10; CI, confidence interval; GTV, gross tumor volume; HR, hazard ratio; N/A, not available; PTV, planning target 
volume; OS, overall survival; LFFS, local failure-free survival; RFS, recurrence-free survival.
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In both studies, further escalation to 90 Gy was asso-
ciated with high rates of pulmonary toxicity, and the maxi-
mum tolerated doses when using 3DCRT were reached at 
83.8 Gy in the study by Bradley14 and 84 Gy in the study 
by Rosenzweig et al.15 SBRT allows for precise delivery of 
high doses of radiation with maximal tissue sparing by using 
aggressive immobilization, motion management, and image 
guidance, allowing for large doses to be delivered with a 
potentially lower rate of pulmonary toxicity than seen with 
conventional techniques. SBRT for the treatment of inoper-
able early-stage lung cancer has been well described and is 
now the standard of care. In a landmark phase I dose-esca-
lation study at the University of Indiana, Timmerman et al.17 
successfully treated 47 patients with T1-T2N0 NSCLC to a 
total dose of 60 to 66 Gy in three fractions.18 Phase I/II data 
from Japan showed a 98% local control rate and 3-year dis-
ease-free survival rates of 72% for stage IA and 71% for stage 
IB cancers treated with 48 Gy in four fractions. OS rates at 3 
years were 83% and 72%,5 respectively, rivaling the outcomes 
seen in surgical series. These results were confirmed by phase 
II studies from the University of Indiana6 and the RTOG.7 
With long-term follow-up, the estimated 3-year local control 
rate at the site of the primary tumor was 88.1% in the Indiana 
study and 97.6% in RTOG 0236. The 3-year OS was 42.7% 
and 55.8%, respectively.
Although earlier series using conventional fractionation 
contained a large representation of tumors greater than 3 cm 
(between 46% and 89% of the study population in the stud-
ies by Sibley et al.,2 Kaskowitz et al.,3 and Wigren et al.4), 
these large tumors make up a significantly smaller percentage 
of modern SBRT studies. Although 51% of tumors treated by 
Fakiris et al.6 were larger than 3 cm, large tumors represent 
only 20% to 30% of treated lesions in most other SBRT stud-
ies.5,7,19 Even when treated with SBRT, larger tumors tend to 
recur more frequently and are associated with a trend toward 
worse survival20 and increased toxicity.18 Given the underrep-
resentation in the literature and concern for increased toxicity, 
we analyzed an exclusive cohort of patients with primary lung 
cancers greater than 3 cm.
When analyzed as a whole, the 1-year LFFS in the cur-
rent study was comparable with that in earlier reported SBRT 
series. The estimated 2-year LFFS of 75.7% was less than 
that in previously published series on SBRT for all tumor 
sizes, including small tumors, for which long-term local con-
trol rates ranged from 88% to 100%.5,7,17 When we examined 
tumors with PTV sizes over a statistically identified cut point 
of 106 cm3, LFFS was statistically significantly worse (56%) 
compared with PTVs less than or equal to 106 cm3, which had 
a 2-year LFFS of 100% (p = 0.05).
Treatment in the current study was generally well toler-
ated. The rate of grade 3 or higher acute and late pulmonary 
toxicity was 14.0%, which is comparable with that in other 
series, which ranged from 4% to 19%.5,6,17 Only one patient 
experienced grade 4 toxicity, and the toxicity attributable to 
SBRT was likely exacerbated by, if not predominantly because 
of, a superimposed synchronous viral and bacterial pneumo-
nia. After appropriate treatment of the pulmonary infections, 
the patient made a full recovery, was discharged and remains 
alive without evidence of disease or long-term toxicity 2 years 
later. There were no grade 5 toxicities. Allowing for the limita-
tions of cross-institutional comparisons of toxicity, the rates of 
acute or late grade 2 or higher respiratory toxicity seemed to 
be slightly higher in our study (31.6%) than the rates in previ-
ously published reports. However, these studies often reported 
only grade 3 or higher toxicity, and rates might be comparable 
with the current study if grade 2 toxicities were included.
A retrospective study from our institution previously 
demonstrated that if the volume of the chest wall receiving 
30 Gy was greater than 70 cm3 in patients treated with SBRT, 
treatment was significantly associated with the development 
of chest wall pain.13 On the basis of these data, we analyzed 
the chest wall V30 in the current study as a dichotomous vari-
able above and below 70 cm3 and found that the development 
of any chest wall pain was significantly associated with V30 
70 cm3 or more, corroborating the previous results and add-
ing a further rationale to the use of this constraint for patients 
treated with SBRT.
It is important to consider the BED that the tumors in the 
current study received. We chose to investigate the cut point 
of BED
10
 100 Gy or more given its established importance 
in the literature. As shown in Table 2, 23 patients received 
BED
10
 doses that were below 100 Gy, which has been shown 
to be associated with inferior local control and OS in previ-
ous reports. However, we did not find BED
10
 less than 100 
Gy to be correlated with significantly worse LFFS, RFS, or 
OS in our study. One possible explanation for this finding is 
that BED
10
 of 100 Gy may not be an adequate dose for larger 
tumors to produce the durable local control and subsequent 
survival benefit seen in early-stage NSCLC. If this were the 
case, comparing LFFS, RFS, and OS above and below the 
cut point of BED
10
 of 100 Gy for the current cohort would 
not show a difference and would be of limited utility. A more 
likely explanation is the moderate number of patients that may 
limit the statistical power to detect dose-dependent differences 
in local control.
The findings of this study are limited by the retrospec-
tive design. Longer follow-up is needed to further assess the 
durability of local control and the possible development of 
further toxicity. The authors also recognize the limitation of 
the PTV cut point. Although it was statistically identified, it 
requires further validation and investigation to clarify its clini-
cal utility. Despite these limitations, the findings of the current 
study are valid and serve as further evidence of the ability of 
SBRT to safely and effectively treat larger lung tumors.
CONCLUSION
To our knowledge, this is the largest report of patients 
limited to tumors more than 3 cm in size treated with SBRT 
for primary lung cancer. The 2-year LFFS in patients with 
PTV 106 cm3 or less was 100% and, although LFFS was sig-
nificantly lower with larger PTV, the rates of LFFS and OS 
reported here are still superior to those rates seen with conven-
tional fractionation, confirming the utility of this technique for 
patients who cannot undergo surgery. Treatment was generally 
well tolerated, with chest wall V30 70 cm3 or more being asso-
ciated with the development of chest wall pain.
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